{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:46:33Z","timestamp":1791920793030,"version":"4.3.4"},"reference-count":62,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,2,7]],"date-time":"2023-02-07T00:00:00Z","timestamp":1675728000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Acute myeloid leukemia (AML) is the most common type of adult acute leukemia. The pathophysiology of the disease has been studied intensively at the cellular and molecular levels. At present, cytogenetic markers are an important basis for the early diagnosis, prognostic stratification and treatment of AML. However, with the emergence of new technologies, the detection of other molecular markers, such as gene mutations and epigenetic changes, began to play important roles in evaluating the occurrence and development of diseases. Recent evidence shows that identifying new AML biomarkers contributes to a better understanding of the molecular mechanism of the disease and is essential for AML screening, diagnosis, prognosis monitoring, and individualized treatment response. In this review, we summarized the promising AML biomarkers from four aspects, which contributing to a better understanding of the disease. Of course, it must be soberly aware that we have not listed all biomarkers of AML. Anyway, the biomarkers we mentioned are representative. For example, mutations in TP53, FLT3, and ASXL1 suggest poor prognosis, low remission rate, short survival period, and often require allogeneic hematopoietic stem cell transplantation. The CEBPA double mutation, NPM1 and CBF mutation suggest that the prognosis is good, the remission rate is high, the survival period is long, and the effect of chemotherapy or autotherapy is good. As for other mutations mentioned in the article, they usually predict a moderate prognosis. All in all, we hope it could provide a reference for the precise diagnosis and treatment of AML.<\/jats:p>","DOI":"10.3389\/fonc.2023.1078556","type":"journal-article","created":{"date-parts":[[2023,2,7]],"date-time":"2023-02-07T07:26:13Z","timestamp":1675754773000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Research progress on molecular biomarkers of acute myeloid leukemia"],"prefix":"10.3389","volume":"13","author":[{"given":"Pei-Yuan","family":"Yin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui-Wen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Jing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-Hua","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai-Min","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,2,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s13045-020-00908-z","article-title":"The global burden and attributable risk factor analysis of acute myeloid leukemia in 195 countries and territories from 1990 to 2017: Estimates based on the global burden of disease study 2017","volume":"13","author":"Yi","year":"2020","journal-title":"J Hematol Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.826768","article-title":"Cellular and molecular biomarkers predictive of response to immunotherapy in acute myeloid leukemia","volume":"12","author":"Wiatrowski","year":"2022","journal-title":"Front Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/ejh.13172","article-title":"Clinical implications of molecular markers in acute myeloid leukemia","volume":"102","author":"Kayser","year":"2019","journal-title":"Eur J Haematol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.blre.2016.08.005","article-title":"Molecular biomarkers in acute myeloid leukemia","volume":"31","author":"Prada-Arismendy","year":"2017","journal-title":"Blood Rev"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2012.00040","article-title":"Genomics of acute myeloid leukemia: The next generation","volume":"2","author":"Riva","year":"2012","journal-title":"Front Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.338","article-title":"Recurrent mutations, including NPM1c, activate a BRD4-dependent core transcriptional program in acute myeloid leukemia","volume":"28","author":"Dawson","year":"2014","journal-title":"Leukemia"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-11-612416","article-title":"Retinoic acid and arsenic trioxide trigger degradation of mutated NPM1, resulting in apoptosis of AML cells","volume":"125","author":"El Hajj","year":"2015","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-1552","article-title":"Risk assessment in patients with acute myeloid leukemia and a normal karyotype","volume":"11","author":"Bienz","year":"2005","journal-title":"Clin Cancer Res"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14051164","article-title":"Role of biomarkers in FLT3 AML","volume":"14","author":"Nitika","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25670","article-title":"Prognostic value of FLT3 mutations among different cytogenetic subgroups in acute myeloid leukemia","volume":"117","author":"Santos","year":"2011","journal-title":"Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/s1658-3876(08)50023-9","article-title":"The challenge of risk stratification in acute myeloid leukemia with normal karyotype","volume":"1","author":"Zaidi","year":"2008","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-02-832360","article-title":"Prognostic factors influencing survival after allogeneic transplantation for AML\/MDS patients with TP53 mutations","volume":"131","author":"Ciurea","year":"2018","journal-title":"Blood"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1605949","article-title":"TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes","volume":"375","author":"Welch","year":"2016","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.218453","article-title":"Synergistic effects of PRIMA-1Met (APR-246) and 5-azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemia","volume":"105","author":"Maslah","year":"2020","journal-title":"Haematologica"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12450","article-title":"Favorable prognosis of biallelic CEBPA gene mutations in acute myeloid leukemia patients: a meta-analysis","volume":"94","author":"Li","year":"2015","journal-title":"Eur J Haematol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1182\/blood-2012-01-403220","article-title":"GATA2 zinc finger 1 mutations associated with biallelic CEBPA mutations define a unique genetic entity of acute myeloid leukemia","volume":"120","author":"Greif","year":"2012","journal-title":"Blood"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/ng.913","article-title":"Heritable GATA2 mutations associated with familial myelodysplastic syndrome and acute myeloid leukemia","volume":"43","author":"Hahn","year":"2011","journal-title":"Nat Genet"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1586\/17474086.2014.903794","article-title":"RARA fusion genes in acute promyelocytic leukemia: A review","volume":"7","author":"De Braekeleer","year":"2014","journal-title":"Expert Rev Hematol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11101591","article-title":"Acute promyelocytic leukemia: Update on the mechanisms of leukemogenesis, resistance and on innovative treatment strategies","volume":"11","author":"Noguera","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1993.tb05889.x","article-title":"RARs and RXRs: evidence for two autonomous transactivation functions (AF-1 and AF-2) and heterodimerization in vivo","volume":"12","author":"Nagpal","year":"1993","journal-title":"EMBO J"},{"key":"B21","doi-asserted-by":"publisher","first-page":"992","DOI":"10.18632\/oncotarget.27513","article-title":"Acute promyelocytic leukemia (APL): a review of the literature","volume":"11","author":"Jimenez","year":"2020","journal-title":"Oncotarget"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1159\/000369242","article-title":"Insights into the all-trans-Retinoic acid and arsenic trioxide combination treatment for acute promyelocytic leukemia: A meta-analysis","volume":"134","author":"Ma","year":"2015","journal-title":"Acta Haematol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2006.07.028","article-title":"A survival study and prognostic factors analysis on acute promyelocytic leukemia at a single center","volume":"31","author":"Xin","year":"2007","journal-title":"Leuk Res"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.27089","article-title":"Acute myelogenous leukemia in adolescents and young adults","volume":"65","author":"Creutzig","year":"2018","journal-title":"Pediatr Blood Cancer"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-01-894980","article-title":"Management of acute promyelocytic leukemia: Updated recommendations from an expert panel of the European LeukemiaNet","volume":"133","author":"Sanz","year":"2019","journal-title":"Blood"},{"key":"B26","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1111\/cge.13372","article-title":"Pathogenetic implication of fusion genes in acute promyelocytic leukemia and their diagnostic utility","volume":"95","author":"Baba","year":"2019","journal-title":"Clin Genet"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12030624","article-title":"Acute promyelocytic leukemia: A constellation of molecular events around a single PML-RARA fusion gene","volume":"12","author":"Liquori","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/7625827","article-title":"Stem cell modeling of core binding factor acute myeloid leukemia","volume":"2016","author":"Mosna","year":"2016","journal-title":"Stem Cells Int"},{"key":"B29","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1053\/shem.2002.36921","article-title":"Molecular genetics of human leukemias: new insights into therapy","volume":"39","author":"Gilliland","year":"2002","journal-title":"Semin Hematol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-707083","article-title":"Beyond KIT in CBF-AML: chromatin and cohesin","volume":"127","author":"Rau","year":"2016","journal-title":"Blood"},{"key":"B31","doi-asserted-by":"publisher","first-page":"3","DOI":"10.2353\/jmoldx.2010.090054","article-title":"Genetic tests to evaluate prognosis and predict therapeutic response in acute myeloid leukemia","volume":"12","author":"Gulley","year":"2010","journal-title":"J Mol Diagn"},{"key":"B32","article-title":"Acute myeloid leukemia-genetic alterations and their clinical prognosis","volume":"11","author":"Lagunas-Rangel","year":"2017","journal-title":"Int J Hematol Oncol Stem Cell Res"},{"key":"B33","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s40364-018-0121-3","article-title":"Acute myeloid leukemia in a father and son with a germline mutation of ASXL1","volume":"6","author":"Seiter","year":"2018","journal-title":"Biomark Res"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.88.23.10735","article-title":"Identification of a gene, MLL, that spans the breakpoint in 11q23 translocations associated with human leukemias","volume":"88","author":"Ziemin-van der Poel","year":"1991","journal-title":"Proc Natl Acad Sci USA"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/ng765","article-title":"MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia","volume":"30","author":"Armstrong","year":"2002","journal-title":"Nat Genet"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021004881","article-title":"Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AML","volume":"6","author":"Menghrajani","year":"2022","journal-title":"Blood Adv"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-03-273532","article-title":"Interfant-99 study group. improved outcome with hematopoietic stem cell transplantation in a poor prognostic subgroup of infants with mixed-lineage-leukemia (MLL)-rearranged acute lymphoblastic leukemia: Results from the interfant-99 study","volume":"116","author":"Mann","year":"2010","journal-title":"Blood"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-02-0434","article-title":"AML with 11q23\/MLL abnormalities as defined by the WHO classification: incidence, partner chromosomes, FAB subtype, age distribution, and prognostic impact in an unselected series of 1897 cytogenetically analyzed AML cases","volume":"102","author":"Schoch","year":"2003","journal-title":"Blood"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.143","article-title":"Acute leukemia working party EBMT. outcome of allogeneic hematopoietic stem-cell transplantation for adult patients with AML and 11q23\/MLL rearrangement (MLL-r AML)","volume":"29","author":"Pigneux","year":"2015","journal-title":"Leukemia"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-05-429274","article-title":"Structural insights into inhibition of the bivalent menin-MLL interaction by small molecules in leukemia","volume":"120","author":"Shi","year":"2012","journal-title":"Blood"},{"key":"B41","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.ccr.2009.11.020","article-title":"DNA Methylation signatures identify biologically distinct subtypes in acute myeloid leukemia","volume":"17","author":"Figueroa","year":"2010","journal-title":"Cancer Cell"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20184576","article-title":"Aberrant DNA methylation in acute myeloid leukemia and its clinical implications","volume":"20","author":"Yang","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2014.10.003","article-title":"Clonal evolution of pre-leukemic hematopoietic stem cells precedes human acute myeloid leukemia","volume":"27","author":"Majeti","year":"2014","journal-title":"Best Pract Res Clin Haematol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/nature13038","article-title":"Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia","volume":"506","author":"Shlush","year":"2014","journal-title":"Nature"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2014.11.004","article-title":"DNA Hydroxymethylation profiling reveals that WT1 mutations result in loss of TET2 function in acute myeloid leukemia","volume":"9","author":"Rampal","year":"2014","journal-title":"Cell Rep"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.28.3762","article-title":"IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication","volume":"28","author":"Paschka","year":"2010","journal-title":"J Clin Oncol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.27.3730","article-title":"IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: A cancer and leukemia group b study","volume":"28","author":"Marcucci","year":"2010","journal-title":"J Clin Oncol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112304","article-title":"Prognostic relevance of integrated genetic profiling in acute myeloid leukemia","volume":"366","author":"Patel","year":"2012","journal-title":"N Engl J Med"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.5645","article-title":"IDH1\/2 but not DNMT3A mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the acute leukemia French association","volume":"6","author":"Debarri","year":"2015","journal-title":"Oncotarget"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-019-03793-7","article-title":"Pharmacokinetics, absorption, metabolism, and excretion of [14C]ivosidenib (AG-120) in healthy male subjects","volume":"83","author":"Prakash","year":"2019","journal-title":"Cancer Chemother Pharmacol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1172\/JCI133344","article-title":"Enasidenib drives human erythroid differentiation independently of isocitrate dehydrogenase 2","volume":"130","author":"Dutta","year":"2020","journal-title":"J Clin Invest"},{"key":"B52","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s12967-018-1445-3","article-title":"MiR-362-5p as a novel prognostic predictor of cytogenetically normal acute myeloid leukemia","volume":"16","author":"Ma","year":"2018","journal-title":"J Transl Med"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.26171","article-title":"Overexpression of miR-216b: Prognostic and predictive value in acute myeloid leukemia","volume":"233","author":"Zhang","year":"2018","journal-title":"J Cell Physiol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0009685","article-title":"Characterization of the melanoma miRNAome by deep sequencing","volume":"5","author":"Stark","year":"2010","journal-title":"PloS One"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-02-408492","article-title":"miR-3151 interplays with its host gene BAALC and independently affects outcome of patients with cytogenetically normal acute myeloid leukemia","volume":"120","author":"Eisfeld","year":"2012","journal-title":"Blood"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.76","article-title":"The expression level of BAALC-associated microRNA miR-3151 is an independent prognostic factor in younger patients with cytogenetic intermediate-risk acute myeloid leukemia","volume":"5","author":"D\u00edaz-Bey\u00e1","year":"2015","journal-title":"Blood Cancer J"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.281","article-title":"MicroRNA expression at diagnosis adds relevant prognostic information to molecular categorization in patients with intermediate-risk cytogenetic acute myeloid leukemia","volume":"28","author":"D\u00edaz-Bey\u00e1","year":"2014","journal-title":"Leukemia"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-014-1237-z","article-title":"High serum microRNA-335 level predicts aggressive tumor progression and unfavorable prognosis in pediatric acute myeloid leukemia","volume":"17","author":"Lin","year":"2015","journal-title":"Clin Transl Oncol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1186\/1746-1596-9-76","article-title":"Prognostic value of miR-96 in patients with acute myeloid leukemia","volume":"9","author":"Zhao","year":"2014","journal-title":"Diagn Pathol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s13046-015-0184-z","article-title":"Low expression of microRNA-204 (miR-204) is associated with poor clinical outcome of acute myeloid leukemia (AML) patients","volume":"34","author":"Butrym","year":"2015","journal-title":"J Exp Clin Cancer Res"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1111\/ijlh.13161","article-title":"Low expression of miR-204 is associated with expression of CD34 and poor performance status in denovo AML","volume":"42","author":"Abdelhafiz","year":"2020","journal-title":"Int J Lab Hematol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.7150\/jca.26391","article-title":"High expression of MiR-98 is a good prognostic factor in acute myeloid leukemia patients treated with chemotherapy alone","volume":"10","author":"Hu","year":"2019","journal-title":"J Cancer"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1078556\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,7]],"date-time":"2023-02-07T07:26:16Z","timestamp":1675754776000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1078556\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,7]]},"references-count":62,"alternative-id":["10.3389\/fonc.2023.1078556"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2023.1078556","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,7]]},"article-number":"1078556"}}